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ARTICLE
Rare truncating variants in the sarcomeric protein
titin associate with familial and early-onset atrial
ﬁbrillation
Gustav Ahlberg1,2, Lena Refsgaard 1,2, Pia R. Lundegaard1,2, Laura Andreasen1,2, Mattis F. Ranthe3,
Nora Linscheid4,5, Jonas B. Nielsen6, Mads Melbye 3,6,7, Stig Haunsø1, Ahmad Sajadieh8, Lu Camp9,
Søren-Peter Olesen2, Simon Rasmussen10, Alicia Lundby4,5, Patrick T. Ellinor 11,12, Anders G. Holst1,
Jesper H. Svendsen 1,6 & Morten S. Olesen1,2
A family history of atrial ﬁbrillation constitutes a substantial risk of developing the disease,
however, the pathogenesis of this complex disease is poorly understood. We perform whole-
exome sequencing on 24 families with at least three family members diagnosed with atrial
ﬁbrillation (AF) and ﬁnd that titin-truncating variants (TTNtv) are signiﬁcantly enriched in
these patients (P= 1.76 × 10−6). This ﬁnding is replicated in an independent cohort of
early-onset lone AF patients (n= 399; odds ratio= 36.8; P= 4.13 × 10−6). A CRISPR/Cas9
modiﬁed zebraﬁsh carrying a truncating variant of titin is used to investigate TTNtv effect in
atrial development. We observe compromised assembly of the sarcomere in both atria and
ventricle, longer PR interval, and heterozygous adult zebraﬁsh have a higher degree of ﬁbrosis
in the atria, indicating that TTNtv are important risk factors for AF. This aligns with the early
onset of the disease and adds an important dimension to the understanding of the molecular
predisposition for AF.
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Atrial ﬁbrillation (AF) is the most common cardiacarrhythmia in clinical practice. At present, >30 millionpeople are affected worldwide1,2. AF is a major risk factor
for stroke, heart failure, and premature death3, making AF a
major public healthcare burden4.
Genome-wide association studies (GWAS) have identiﬁed 97
common AF susceptibility loci5,6 and candidate gene studies have
implicated rare genetic variants in a number of genes7, primarily
encoding cardiac ion channels. Recent GWAS have associated AF
with genetic loci located in the proximity of genes encoding
structural proteins, such as SYNPO2L8 and TTN5. Furthermore,
two studies9,10 have independently identiﬁed an association
between early-onset AF and a rare variant in the myosin-coding
gene MYL4. These recent ﬁndings suggest that AF could be
caused by atrial cardiomyopathy11,12. Identifying highly predis-
posing genetic variants could lead to a better understanding of the
underlying pathophysiological mechanisms and provide better
means for risk stratiﬁcation and treatment of AF.
In the present study, we investigate the genetic background of
familial and early-onset AF, aiming to identify genes involved in
AF pathology. We perform whole-exome sequencing of families
with three or more family members affected by AF. In these
families, we ﬁnd an increased burden of TTN mutations, which is
replicated in an independent lone AF cohort. Using a zebraﬁsh
model carrying an I-band truncating mutation in ttn.2, we show
that heterozygous mutants have a distinct sarcomere defect. Fur-
ther analyses of the heart reveal an increased amount of ﬁbrosis in
mutant ﬁsh, suggesting a predisposition for arrhythmia and con-
duction disease. In line with these ﬁndings, electrocardiographic
analysis of adult zebraﬁsh reveal an electrophysiological defect,
represented by prolonged PR interval, a well-recognized marker
for increased risk of AF.
AF has traditionally been described as an electrical disease of
the heart. Our current study indicates that defects in genes
involved in the structural architecture of the heart also play a
signiﬁcant role in the development of AF.
Results
Study subjects. Family cohort: Twenty-four families were eligible
for inclusion (at least three participating family members had an
AF diagnosis) and agreed to participate, resulting in 77 AF cases
in total (Supplementary Fig. 1).
Early-onset lone AF: A total of 399 patients were recruited
using the Danish National Patient Registries. Only patients with
onset of disease before the age of 40 with no known AF risk
factors and normal echocardiography were included. Summary
characteristics of the early-onset lone AF cohort are presented in
Table 1.
Two control groups were included in the study. Control group
A consists of 663 individuals in an exome-sequenced subpopula-
tion from the Inter99 study13,14, further described in the Methods
section. Control group B consists of 383 individuals without
cardiac disease, who have undergone cardiac examination and
Holter monitoring as part of the Copenhagen Holter Study15.
Inclusion of families. With the use of the Danish National
Registries16, we identiﬁed all Danish families with three or more
members diagnosed with AF. In total, 67 families with 213 AF
cases were identiﬁed. These were contacted by mail with an
invitation to participate in the study. We were unable to contact
20 AF cases, due to unknown addresses. Thirty-one invited
individuals replied that they did not wish to participate and 49
did not reply. One hundred thirteen individuals, from 42 families,
accepted the invitation. In order to be included into the cohort, at
least three members, from the same family, with the diagnosis of
AF had to agree to participate, e.g., if less than three family
members agreed, the family was not included. Twenty-four
families fulﬁlled the inclusion criteria, which resulted in 77 AF
cases for exome sequencing.
Evaluation of sample quality and population structure. The
minimum call rate in AF family exomes was 98.4% and in control
exomes 97.0%. Eight control exomes were excluded on the basis of a
singleton rate > 4 standard deviations (SDs). A high singleton rate
could imply ancestry of unmatched ethnicity. We then analyzed the
population structure in our groups with Multidimensional Scaling
Analyses (MDS) using unrelated 1000 genomes project samples as
reference (n= 25,455 single-nucleotide polymorphisms (SNPs);
linkage disequilibrium (LD) threshold > 0.5; minor allele frequency
(MAF) > 1%, excluding non-autosomal and monomorphic var-
iants). Three control samples were considered ethnic outliers
(Supplementary Fig. 2). The ﬁxation index (Fst) was estimated to
0.00122, between index patients and controls (samples n= 687,
SNPs n= 22,745). The MDS and relationship analyses agreed with
reported ethnicity and relatedness and we did not observe any batch
effects (Supplementary Figs. 3, 4, Supplementary Table 1).
Samples in the replication study that did not meet quality
control criteria and ethnic outliers were excluded (see Methods).
The MDS analyses agreed with reported ethnicity (Supplementary
Fig. 5). We included 770 ethnically matched and unrelated
individuals for a subsequent burden test (lone AF cohort= 395;
control group B= 375).
Sequencing coverage. The mean depth of coverage in control
exomes was 82.1X (SD= 13.3, n= 663) and in AF family exomes
94.6X (SD= 11.4, n= 77) (excluding non-autosomal and ﬁltered
regions). Constitutively cardiac expressed TTN exons (percent
spliced in [PSI] > 90) were considered low coverage if < 80% of
samples in either the case or the control group were covered with
<20X reads on average. Sixteen TTN exons had low coverage and
Table 1 Baseline characteristics of the early-onset lone AF
cohort
Early-onset lone
AF (n= 399)
Control group B
(n= 383)
Sex, male (n (%)) 334 (84%) 257 (67%)
Age, years (median (IQR)) 28 (23–33)a 71 (66–76)b
Height, cm (mean (SD)) 183 ( ± 8.9) 172 ( ± 8.8)
Weight, kg (mean (SD)) 91.4 ( ± 49.1) 77.4 ( ± 14.7)
BMI, kg m–2 (mean (SD)) 27 ( ± 15.5) 26.4 ( ± 4.9)
Smoking, current or
previously (n (%))
119 (29%)
Alcohol consumption per
week (mean (SD))
6.0 ( ± 7.2)
Hypertension (n (%)) 0 (0%) 246 (64.4%)
Diabetes (n (%)) 0 (0%) 39 (10.2%)
Heart failure (n (%)) 0 (0%) 0 (0%)
Myocardial infarction (n (%)) 0 (0%) 0 (0%)
Valvular heart disease (n
(%))c
0 (0%) 0 (0%)
Type of AF (n (%))
Paroxysmal 246 (62%)
Persistent 126 (32%)
Permanent 23 (6%)
Family history, self-reported
(n (%))
157 (39%)
AF: atrial ﬁbrillation, IQR: interquartile range, SD: standard deviation
aAF onset age
bAge at enrolment
cSevere mitral regurgitation, aortic stenosis, tricuspid regurgitation, or ≥mild mitral stenosis
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were not included in subsequent analysis (Supplementary Fig. 6).
These exons amount to ~4% of the coding bases in TTN cardiac
expressed isoforms (PSI > 90).
In the replication study, we employed a target deep sequencing
approach. The mean depth of coverage of TTN in the lone AF
cohort and control group B was 833X (SD= 155, n= 770). The
mean depth of coverage in the lone AF group and control group B
were 877X (SD= 135, n= 395) and 900X (SD= 173, n= 375),
respectively. For each sample included in the replication test, >
99% of the targeted bases within TTN were covered at least 20
times.
Genetic variation. Whole-exome sequencing analysis was per-
formed on the 24 families in the familial AF cohort (n= 77) and
was compared with control group A (n= 663). We aimed to
identify rare loss-of-function (LOF) variants with an autosomal
dominant disease pattern and high penetrance. Only family
members with the diagnosis of AF were taken into consideration,
since 40–80% of all AF episodes are asymptomatic17,18.
In 16 out of 24 families, we identiﬁed rare co-segregating LOF
variants (Supplementary Data 1). Five of the 24 families (21%) had
a predicted LOF variant, i.e., stop-gain-, frameshift-, or splice site
variants, in well-established cardiomyopathy disease-causing
genes. Four plausible pathogenic titin-truncating variants (TTNtv)
(ENST00000589042; c.6508 G > T, c.79101 T > A, c.11952 C > A,
c.98300delT) and one LOF variant in DSC2 (ENST00000280904;
c.475-1 G > T) were identiﬁed among ﬁve unrelated families
(Fig. 1, Table 2). All variants co-segregated with disease, however,
this does not imply a monogenetic cause. Post analysis, we looked
for rare missense variation in genes previously associated with
familial AF (GJA5, KCNA5, KCNE2, KCNJ2, KCNQ1, KCNH2,
NPPA, and SCN5A), which was absent9.
To validate this ﬁnding, we investigated the variation of rare
TTNtv in an early-onset lone AF cohort and control group B.
Summary characteristics of the early-onset lone AF cohort are
presented in Table 1. Sixteen rare TTNtv, distributed among 18
early-onset lone AF cases (4.7%), were identiﬁed (Supplementary
Data 2). All identiﬁed variants reside in constitutive exons (PSI ≥
90) and are incorporated into the two principal cardiac isoforms
(N2BA and N2B). Among these, 11 are found in the A-band, 6 in
the I-band, 4 in the M-line, and 1 in the Z-disc (Supplementary
Fig. 7). All identiﬁed TTNtv, except one, were absent from the
Exome Aggregation Consortium (ExAC) database (Supplemen-
tary Data 2).
Association tests of TTNtv. We tested the association between
TTNtv and AF using familial AF cases and control cohort A. A
generalized linear mixed model (GLMM) burden test with TTNtv
revealed a signiﬁcant association between AF and TTNtv (AF
family members= 76, control group A= 663, P= 1.76 × 10−6).
This result corresponds to a TTNtv (PSI ≥ 90) frequency of 16.7%
in the familial AF cohort and 0.5% in the control population.
Seventeen rare TTNtv were identiﬁed in the early-onset lone
AF cohort and no TTNtv were identiﬁed in control group B
(allele count cases= 18, allele count controls= 0). Using Firth
logistic regression, a signiﬁcant association between TTNtv and
early-onset lone AF was replicated in the early-onset lone AF
cohort and control group B (odds ratio [OR]= 36.8, 95%
conﬁdence interval [CI]= 5.0–4692.5, P= 4.13 × 10−6).
Clinical characteristics of TTNtv carriers. All TTNtv carrying
family members had early-onset AF (age of onset ≤ 65 years;
median age of onset= 40 years) and had been examined with
echocardiographic examinations and a revision of medication
history (Fig. 1, Table 3, Supplementary Table 2). The clinical data
suggest that left atria (LA) dilations could be tachycardia-induced
(Table 3). For example, M1023_III-3 was diagnosed with AF at
the age of 25 (LA diastolic diameter= 38 mm; left ventricle
ejection fraction [LVEF]= 66%). In relation to an episode of
persistent AF with high ventricular rate occurring 27 years after
diagnosis, the same patient developed mild LA dilation, heart
failure, and a mildly dilated left ventricle (LV) (LA= 44 mm;
LVEF= 25%; LV diastolic diameter= 56 mm; Table 3). Inter-
estingly, just 2 weeks prior to the described event, a pre-planned
echocardiography with normal ﬁndings was performed. Also,
E003_II-2 developed severely dilated atria at the time of transi-
tion from paroxysmal to persistent AF, with normalization after
rate control. This patient’s latest available echocardiography (18
years after AF diagnosis) was normal, demonstrating complete
remission. A genetic predisposition for structural changes in the
atrial myocardium with increased arrhythmia burden therefore
seems plausible (Fig. 1). Three out of 15 patients (E003_III-4,
M1023_III-1, and M1039_III-3) were diagnosed with dilated
cardiomyopathy (DCM) at the same time as their AF diagnosis.
Two out of these three had echocardiographic remission after
frequency control of their AF, indicating tachycardia-induced
disease.
The median age of onset for TTNtv carriers in the early-onset
lone AF cohort was 26 (Supplementary Data 2). None of the
carriers had known risk factors for AF at the time of diagnosis.
Echocardiographic examinations at the time of AF diagnosis or
earliest possible thereafter, showed normal echocardiographic
parameters for all carriers, with regard to LV dimensions, LA size,
and LVEF. One patient, patient 2, had a moderately enlarged LA,
but normal ventricular size and function, and the LA dilation was
considered tachycardia induced. Follow-up clinical echocardio-
graphic examinations, some performed decades after the AF
diagnosis, have revealed normal heart function and ventricular
sizes (a total of 200 person-years of life after AF diagnosis;
median follow-up= 9 years; Supplementary Data 2). To date,
none of the TTNtv carriers have been diagnosed with DCM.
Proteomics. Proteomics experiments were conducted to evaluate
the protein expression level of titin in human atria compared with
human ventricles. Titin is among the 10 most abundant proteins
in the human heart evaluated by high-resolution mass spectro-
metry (MS) measurements (Supplementary Fig. 8a). The phy-
siological role of titin has predominantly been investigated in the
ventricles, and we did not ﬁnd a statistically signiﬁcant difference
between the protein expression levels of titin in the atria com-
pared with the LV (Supplementary Fig. 8b).
Zebraﬁsh model. Defects in sarcomere assembly in early devel-
opment would suggest that TTNtv predispose both chambers for
disease, independent of long-term systemic effects. To address the
molecular consequences of a TTNtv in early cardiac development,
we used the zebraﬁsh as a model. Zou et al. have previously
shown that a CRISPR/Cas9 generated homozygous mutant car-
rying an N-terminal truncated variant of titin, ttn.2sfc9, displayed
a severe sarcomere defect19. The truncation is in proximity to one
of the patient-speciﬁc mutations identiﬁed in the current study,
and this mutant zebraﬁsh was used to further investigate the
potential effects of TTNtv. The Z-discs of WT, heterozygous, and
homozygous larvae were stained with the z-disc protein, alpha-
actinin, and visualized with confocal microscopy (Supplementary
Figs. 9–11). We replicated the previous ﬁndings by Zoe et al.,
where the WT and heterozygous larvae appeared with normal
Z-discs, whereas the homozygous mutants showed a severe sar-
comere defect, with absent Z-discs. The homozygous variant in
zebraﬁsh is embryonic lethal, and the larvae die around 5 days
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E003, TTN c.6508 G>T
M1018, TTN c.79101 T>A
M1030, DSC2 c.475-1 G>T
M1039, TTN c.98300delT
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AF onset 40
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Cardiac
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III-2
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III-3
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III-5
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III-4
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DM2
II-5
IV-1 IV-2
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AF onset 42
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M1023, TTN c.11952 C>A
Fig. 1 Pedigrees of the families with TTNtv and a loss-of-function variant in DSC2. Square: male. Circle: female; Black ﬁlled: AF affected individual; White
ﬁlled: unaffected individual; Gray ﬁlled: individual with symptoms of heart disease; Diagonal line: diseased individual. Presence of mutation is indicated with
+ for presence and – for absence (persons with available exomes). Patient II_6 also had thyroid disease and aortic regurgitation. Tachy.Ind.: tachycardia
induced, HF: heart failure, AMI: acute myocardial infarction, DM2: diabetes type 2, HCL: hypercholesterolemia, DCM: dilated cardiomyopathy
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post fertilization. All patients carrying TTNtv in this study were
heterozygous adults and we therefore decided to study the adult
ﬁsh. To observe the sarcomere in greater detail, we performed
transmission electron microscopy (TEM) on isolated hearts from
early larval stage (WT, homo- and heterozygous), adult hetero-
zygous and WT ﬁsh. The TEM analysis revealed a sarcomere
defect in both atria and ventricle of the adult and larval hetero-
zygous mutants (Fig. 2, Supplementary Figs. 1, 2). Adult mutants
showed highly disorganized sarcomeres in both chambers, with
poorly deﬁned Z-discs and absent I-bands and M-lines. Fur-
thermore, the myoﬁbril structure appeared loose and the sarco-
mere length was signiﬁcantly shorter (Supplementary Figs. 1, 3,
Supplementary Tables 3, 4).
Studies of electrical function using electrocardiogram (ECG)
analyses showed a prolonged PR interval in the heterozygous
zebraﬁsh (Supplementary Table 5).
With the use of Sirius Red staining, we investigated the amount
of ﬁbrosis in the heterozygous ttn.2sfc9 adults and WT adult
zebraﬁsh. The staining revealed a higher degree of ﬁbrosis in the
atria of the mutant ﬁsh as compared with their WT siblings
(Fig. 3).
Discussion
We identiﬁed a signiﬁcant enrichment of TTNtv in patients with
familial AF (P= 1.76 × 10−6). The association was validated in an
independent cohort of early-onset lone AF cases (OR= 36.8, P=
4.13 × 10−6). This result suggests TTNtv to be a major genetic
contributor to AF, adding a substantial risk to this complex
oligogenic trait. The TTN gene encodes the giant sarcomere
protein titin that is highly expressed in all chambers of the human
heart (Supplementary Fig. 8). It is well known that TTN dys-
function can alter ventricular cardiomyocyte structure through its
involvement in multiple functions such as sarcomere assembly
and passive elasticity of muscles20. TTNtv have previously been
strongly associated with cardiomyopathies21 and some studies
have reported an increased burden of arrhythmias among DCM
patients with TTNtv22,23. Schafer et al. showed that TTNtv
encoded into cardiac exons (PSI > 15) is found in approximately
0.5% of the general population, which give rise to a continuum of
phenotypes and compromises both metabolic function and car-
diac performance24. Our result is congruent with this estimate,
since 0.5% in control group A had TTNtv, whereas 16% of
patients with familial AF and 4.7% of patients with early-onset
lone AF had TTNtv. All rare TTNtv identiﬁed in the AF families
and early-onset lone AF cases resides in constitutively expressed
exons incorporated into the two principal cardiac isoforms21. The
occurrence rate of TTNtv in control group B (frequency of TTNtv
[PSI > 90] < 0.27) could be due to the fact that these individuals
were free from cardiac diseases. All individuals had undergone
cardiac examination and Holter monitoring without detecting
any sign of arrhythmia. Furthermore, in accordance with our
results, two recent GWAS have associated common TTN variants
to AF susceptibility5,25.
The clinical data among TTNtv carriers in the families suggest
that LA dilation could be tachycardia induced (Table 3), as pre-
viously shown26. An essential feature of the patients belonging to
the early-onset AF cohort is that they had all undergone extensive
Table 2 AF-associated loss-of-function variants in AF families
Family Gene Genomic position (hg19) Variant Consequence ExAC MAF GERP score Exon PSI
E003 TTN 2:179640083 c.6508 G > T Splice site 0 5.27 28 100
M1023 TTN 2:179606008 c. 11952 C > A Stop-gain 0 5.87 49 100
M1018 TTN 2:179431758 c.79101 T > A Stop-gain 0 5.62 327 100
M1039 TTN 2:179404492 c.98300delT Frameshift 8.3 × 10–6 NA 353 100
M1030 DSC2 18:28669558 c.475-1 G > T Splice site 0 6.16 (Intron 4) NA
AF: atrial ﬁbrillation, ExAC: Exome Aggregation Consortium, GERP: genomic evolutionary rate proﬁling, PSI: percent spliced in
Table 3 Clinical information on the TTNtv and DSC2 loss-of-function carriers in the AF families
Family Pedigree
ID
Sex AF onset
age
Age Comorbidities/risk factors
for AFa
ECHO, at AF diagnosis or earliest available ECHO, latest available
LVDD
(mm)
LA
(mm)
LVEF
(%)
Years from AF
diagnosis
LVDD
(mm)
LA
(mm)
LVEF
(%)
Years from AF
diagnosis
E003 II-2 M 42 62 Nb Sdb 40–45c 16 Nb 40 55 18
E003 II-5 F 58 71 HTN, HT Nb 45 Nb 4 Nb Sdb Nb 10
E003 III-4 M 37 47 NIDCM 67 57 15 0 70 56 30–35 8
M1023 II-4 F 63 71 Nb Nb 35c 0 60 32 25c 7
M1023 III-1 M 40 50 NIDCM 67–71 51 20 3 54 44 43c 11
M1023 III-3 F 25 52 49 38 66 22 56 44 25c 27
M1018 III-1 M 65 69 Multid Sdb Sdb Nb 0 Mild
CLVHb
Db 60 3
M1018 IV-2 M 28 38 HTN Nb Nb Nb 0 Nb Nb Nb 0
M1018 IV-3 M 31 40 Nb 34 Nb 0 Nb Nb 60 7
M1039 III-2 M 23 50 Nb Nb Nb 16 55 Nb 60 24
M1039 III-3 M 39 51 NIDCM Sdb N.A. 30c 5 Moderat
Db
Nb 50–55 8
M1039 III-5 M 25 37 Nb Nb Nb 9 Nb Nb 60 11
M1030 III-4 M 49 63 HCL Nb Db Nb 0 Nb Db Nb 0
M1030 III-7 F 50 72 Mild H Mild
Db
Nb 10 Mild H Mild
Db
Nb 0
M1030 IV-5 M 41 46 52 43 Nb 0 52 43 Nb 0
AF: atrial ﬁbrillation, LVDD: left ventricular diastolic diameter, LA: left atrial diameter, LVEF(%): left ventricular ejection fraction (%), D: dilated, H: hypertrophy, HT: hyperthyroidism, HTN:
hypertension, HCL: hypercholesterolemia, NIDCM: nonischemic dilated cardiomyopathy, M/F: male/female, N: normal, Sd: severely dilated, CLVH: concentric left ventricular hypertrophy, TTN: titin,
TTNtv: titin-truncating variants, DSC2: desmocollin 2, N.A.: not available, ECHO: echocardiography
aDiagnosed before or within 12 months after the AF diagnosis
bExact values not provided
cDuring AF
dHypertension, stroke, aortic-, and mitral prolapse and regurgitation (biological aortic valve and mitral valve repair), dilated LV
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clinical screening, due to their diagnosis at such a young age. Yet,
no known comorbidities were identiﬁed in these patients and
none of the 18 early-onset lone AF TTNtv carriers have devel-
oped DCM after their AF diagnosis. Furthermore, echocardio-
graphic examinations of up to 41 years after the AF diagnosis
were normal. In this cohort, there is a ~10-fold increase in
TTNtv, residing in constitutively expressed exons, compared with
the general population. The clinical ﬁndings and the association
of TTNtv to early-onset lone AF in our study suggest that TTNtv
predisposes directly for AF.
Other cardiac structural genes have recently been associated
with AF. Two different variants in the sarcomere protein gene
myosin light chain 4 (MYL4) have in three independent studies
been associated with familial early-onset AF9,10,27. Gudbjartsson
et al.10 performed whole-genome sequencing of the Icelandic
population and identiﬁed a founder frameshift variant in MYL4,
associated with a recessive form of AF. Orr et al.9 reported a novel
heterozygous MYL4 variant in a family that in addition to early-
onset AF also displayed signs of a primary atrial myopathy. When
performing an overexpression ofMYL4 in zebraﬁsh they observed
both structural and electrical abnormalities associated with atrial
cardiomyopathy and AF in humans.
Also, the protein product of the gene SYNPO2L which is
expressed in the cardiac muscle, localized at the Z-disc and
interacting with a number of other actin proteins, have been
associated with AF5,8. The ﬁndings from the studies listed above
support an emerging hypothesis of atrial cardiomyopathy as a
mechanism that predisposes for AF.
From proteomics experiments, we conﬁrmed that titin is highly
expressed in the heart with no statistically signiﬁcant difference
between the protein expression level in the atria compared with
the LV (Supplementary Fig. 8). The high expression level of titin
in human atria suggests that TTNtv also should impact the atria.
To investigate this, we used a CRISPR/Cas9 modiﬁed zebraﬁsh
carrying a N-terminal truncated variant of ttn.2 (the cardiac-
speciﬁc zebraﬁsh orthologue of human TTN). We conﬁrmed
previous ﬁndings using immunostaining of isolated hearts from
72 h post fertilization (hpf) old ttn.2sfc9 homozygous mutant and
heterozygous ﬁsh. Homozygous zebraﬁsh showed complete loss
of the Z-discs in both atria and ventricle from an early larval
stage, indicating a defective sarcomere structure in embryonic
development and die around 5 days post fertilization (Supple-
mentary Figs. 9–11). Heterozygous mutants appear phenotypi-
cally normal when evaluating the Z-discs in both atria and
2 µm 2 µm
2 µm 2 µm
a b
c d
Fig. 2 Compromised sarcomere structure in adult heterozygous zebraﬁsh mutants. TEM images (13,500 × ) from adult atria (a, b) and ventricles (c, d).
a WT atria show well-deﬁned sarcomeres, with distinguishable Z-discs (red arrows) and I-bands (yellow arrows) throughout the tissue. Scale bar 2 µm.
b In heterozygous mutant atria the sarcomere structure is less organized. The Z-discs appear blurred (red arrows), and the I-bands are absent
(yellow arrows). Scale bar 2 µm. c Ventricle sarcomeres appear well deﬁned in WT siblings, with clear Z-discs (red arrows), I-bands (yellow arrows),
and M-lines (blue arrow). Scale bar; 2 µm. d In heterozygous mutants, there is a distinct lack of I-bands and M-lines, and the Z-discs appear blurry
and increased in thickness (Scale bar; 2 µm). The length of the sarcomeres, as measured from Z-disc to Z-disc, are signiﬁcant different between WT
and heterozygous in atria
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ventricle. This is in accordance with previous reports on this
mutant19. However, on closer inspection using TEM, the Z-discs
of heterozygous mutants in the early larval stage appeared less
deﬁned as compared with WT siblings (Supplementary Fig. 12).
Since our human TTNtv carriers are adults and heterozygous for
the mutation, we focused on the heterozygous adult zebraﬁsh
mutant. TEM in adult heterozygous zebraﬁsh revealed missing
M- and I-lines in both atria and ventricle (Fig. 2). The sarcomere
in the heterozygous adult hearts appeared disorganized with
shorter sarcomere length and with unstructured Z-discs. Previous
reports have investigated the presence of Z-disc as the hallmark of
sarcomere integrity in titin truncations19. However, our data
suggest that not only the Z-disc, but also the M-line and I-band
are affected, since TEM imaging revealed a widespread sarcomere
dysfunction in the atria.
TTNtv in cardiomyopathy patients have been shown to aug-
ment ventricular interstitial ﬁbrosis and increase ventricular
arrhythmias28. We speculated whether this mechanism could also
be applied to the atria and cause AF. We therefore stained for
ﬁbrosis in adult hearts from WT zebraﬁsh and their heterozygous
siblings. The heterozygous ttn.2sfc9 adults did indeed have a
higher degree of ﬁbrosis in the atria, indicated by the Sirius Red
staining (Fig. 3). Furthermore, ECG analyses showed electro-
physiological defects with prolonged PR interval (Fig. 3, Supple-
mentary Table 5). PR interval prolongation has recently been
associated with AF29.
Atrial ﬁbrosis has continuously been reported to be more fre-
quent in patients with AF compared with non-AF patients30–33.
Subsequent studies have revealed that patients with atrial ﬁbrosis
have a high re-entrant activity, offering a likely explanation for
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Fig. 3 Truncating mutation in ttn.2 cause increase ﬁbrosis and electrophysiological defects in adult heterozygous mutants. Sirius staining of isolated whole
hearts from adult WT (a) and heterozygous mutant siblings (b) show increased ﬁbrotic lesions in the heterozygous heart (b) compared with the WT (a).
This increase appears to be more pronounced in the atria of the heterozygous hearts (d) (n= 4) compared with that of the WT siblings (c) (n= 4). Scale
bars: a, b 200 µm; c, d; 50 µm. ECG surface recordings of adult WT ﬁsh (e) revealed a regular ECG pattern with well-deﬁned P-waves and QRS complexes,
with regular PR intervals (g) and RR intervals, with low beat-to-beat variability, as shown by the Poincaré plot (h), indicative of a regular heart rhythm (n=
8). In the heterozygous siblings, the ECG pattern was equally well deﬁned (f), but with a larger PR interval, compared with the WT siblings. Furthermore,
the RR interval and beat-to-beat variability was irregular, as demonstrated by the Poincaré plot (i), indicating an irregular heart rhythm in the heterozygous
siblings (n= 8)
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the increased burden of AF in these patients34,35. A few studies
have included patients characterized as lone AF patients and even
these patients display some amount of structural remodeling of
the LA36,37 with Mahnkopf et al. reporting that approximately
one-fourth of the lone AF patients had moderate amounts of
atrial ﬁbrosis37. Based on these ﬁndings, Kottkamp32 suggested
to reclassify some lone AF patients as having “ﬁbrotic atrial
cardiomyopathy”.
The ﬁnding of atrial ﬁbrosis in the young adult zebraﬁsh
(~8 months of age) indicates that TTNtv predispose to the
development of ﬁbrosis in the atria from an early age. The early
onset of AF in both investigated patient cohorts in the present
study seems consistent with the zebraﬁsh ﬁndings and provide a
plausible link between structural disease and the electrical phe-
notype. However, we cannot exclude that other non-genetic fac-
tors, such as inﬂammation, might in concert with TTNtv cause an
increased level of ﬁbrosis.
According to current guidelines, catheter ablation of parox-
ysmal AF is a class I recommendation after failure of antiar-
rhythmic drug therapy38. If a patient’s AF seems to result from
atrial cardiomyopathy, it raises the question whether the patient
could beneﬁt from AF ablation, a dilemma recently discussed by
Nattel and Dobrev39 as AF patients with high amount of ﬁbrosis
have been shown to have a higher recurrence of post-ablation
AF35,40–42. Interestingly, recent results from the CASTLE-AF
trial37 show a number of beneﬁcial effects of catheter ablation in
AF patients with associated heart failure. The ongoing DECAAF
II study43,44 investigating whether delayed enhancement mag-
netic resonance imaging-guided ﬁbrosis ablation has better out-
comes than traditional ablation techniques, might help address
some of these issues. In conclusion, we found a signiﬁcant
enrichment of TTNtv in familial and early-onset lone AF. Using a
zebraﬁsh model, we showed that both larvae and adult TTN
truncated ﬁsh have a compromised sarcomere structure and
increased ﬁbrosis in the atria. Furthermore, the heterozygous
mutants also display an electrophysiological phenotype indicating
a predisposition for arrhythmia. These data suggest that the atria
are predisposed for disease independent of long-term systemic
effects. Compromised sarcomere structure in the atria add a new
dimension to the understanding of this common disease, as AF
traditionally has been considered an electrophysiological disease.
Methods
Study subjects. Familial AF cohort: Danish families with three or more family
members diagnosed with AF were identiﬁed by the use of the Danish National
Registries (The Civil Registration System, The National Patient Register, and The
Danish Family Relations Database16). Danish citizens are assigned a unique per-
sonal identiﬁcation number, which is registered in all contacts with public
authorities enabling a complete survey of cases. AF was deﬁned as a discharge
diagnosis in the presence of the International Classiﬁcation of Diseases (ICD)-8
code 427.93, 427.94, and ICD-10 code I48. The AF diagnosis obtained from the
Danish National Patient Register has previously been proved valid, with a positive
predictive value of 92.6%45. Individuals who agreed to participate had blood
samples drawn, used for whole-exome sequencing, and clinical information was
obtained through a questionnaire and review of patient health records. Written
informed consent was obtained from all study participants. The study was
approved by the scientiﬁc ethics committee for the Capital Region of Denmark
(protocol number H-1-2011-044).
Early-onset lone AF cohort: A total of 399 unrelated early-onset AF subjects
were recruited using the Danish National Patient Registries and ICD-10 code I48.9.
Only patients with onset of disease before the age of 40 were included. Patients
with cardiovascular diseases (mitral valve/aortic valve disease, ischemic heart
disease, congestive heart failure, cerebral-vascular stroke, congenital heart
malformation, and cardiomyopathy), or speciﬁc systemic diseases
(hyperthyroidism, hypertension, and diabetes)16 and/or with an abnormal
echocardiography at the time of their AF diagnosis were excluded. Individuals
fulﬁlling inclusion criteria were given written information and offered to
participate. Blood samples and clinical data were collected. The study was approved
by the scientiﬁc ethics committee for the Capital Region of Denmark (protocol
number H-1-2011-044). All included patients gave written informed consent.
Control group A: The control population was drawn from an exome-sequenced
subpopulation from the Inter99 study (CT00289237, ClinicalTrials.gov), previously
described in detail by Glümer et al.8 and Lohmueller et al.14. All participants were
of self-reported Danish origin. This population was assumed to be representative of
the general population (only AF affected individuals were excluded). From this
population, we included all subjects who fulﬁlled our sequencing quality control
criteria. The study was approved by the scientiﬁc ethics committee for the Capital
Region of Denmark. All included patients gave written informed consent.
Control group B: Blood samples from 384 healthy men and women between 55
and 75 years of age and without a history of cardiovascular disease or stroke from
the Copenhagen Holter Study10 were used as controls. Informed consent was
obtained from all participants. The study protocol was approved by the local ethics
committee (KF 01 313322, KF 01 25304).
DNA sequencing and genotyping. Genomic DNA extracted from blood samples
was used to construct DNA libraries. Whole-exome sequencing was performed on
the familial AF cohort and control group A. In brief, ConGenomic DNA was
extracted from peripheral blood using Maxwell 16 LEV Blood DNA Kit. The
familial AF exomes were sequenced on Illumina HiSeq 2500 using Broad Institute
(BI) bait capture kit (38 Mb target region). The control group A’s exomes were
sequenced with an Illumina HiSeq 2000 using Agilent SureSelect All Exon Kit v.2
(46 Mb target region), as previously described15.
Targeted deep sequencing of TTN was performed on the lone AF cohort and
control group B. The study subjects’ DNA was fragmented by endonucleases and
hybridized to biotinylated gene-speciﬁc probes incorporating Illumina paired-end
sequencing motifs and indexed primers (Illumina TruSight cardio sequencing kit).
The hybridized molecules were captured with magnetic beads, PCR ampliﬁed, and
sequenced with the Illumina systems (HiSeq 2500 and NextSeq).
Raw reads were trimmed from adapter sequences and low-quality reads were
ﬁltered. Subsequently, alignment of reads were made to the to the human reference
genome (NCBI Genome Build 37) with Burrow-Wheelers Aligner mem
algorithm46. The alignments were post-processed according to Genome Analysis
Toolkit version 3.4 (GATK) guidelines47. We performed a joint genotyping analysis
on all exomes with Haplotypecaller/GATK v3.4 and on samples sequenced with
targeted deep sequencing with Uniﬁedgenotyper/GATK v3.7.
Evaluation of variants and samples in exomes. Variant calling was performed
with Haplotypecaller/GATKv.3.4 in the intersecting region of the two exome
capture kits. The intersect region had 33Mbp. Subsequently, variants were ﬁltered
using GATKv.3.4’s tool VQSR with annotations:
anQD an FS an SOR  anMQRankSuman ReadPosRankSum
The ﬁltering level threshold for sensitivity was set to 99.5% for SNPs and 99.0% for
indels.
Hard ﬁltering thresholds were set to:
QD<2:0; FS>200:0;MQ<40:0;ReadPosRankSum< 30:0
On a genotype level, calls with a genotype quality < 20 or read depth < 10 were
discarded. Subsequently, variants with a missing rate > 20% or a Hardy–Weinberg
equilibrium P < 5 × 10–6, calculated on family index patients and controls, were
ﬁltered.
Samples with a transition to transversion ratio (TiTv) or hetero-/homozygosity
rate and singleton rate exceeding four SDs were excluded from further analyses.
Evaluation of variants and samples in targeted sequencing. In the targeted
deep sequencing approach, variants were called with the software tool Uni-
ﬁedgenotyper/GATK v3.7 in the protein-coding region of TTN that corresponds to
the meta-transcript of ENSG00000155657, and a padding of 100 bp was added on
ends of each exon region.
Hard ﬁltering thresholds were set to:
QD<2:0; FS>60:0;MQ<40:0; ExcessHet>20:0;
MQRankSum< 20:0;ReadPosRankSum< 20:0
On a genotype level, calls with a genotype quality < 20 or read depth < 10 were
discarded. Subsequently, any variants with a missing rate > 10% were excluded.
Samples with a call rate < 95% were excluded. Samples with a TiTv ratio or hetero-/
homozygosity rate and singleton rate exceeding four SDs were excluded.
The genetic distances were estimated with identity by state and MDS, using
unrelated 1000 genomes project samples as reference (Supplementary Fig. 6). We
considered samples exceeding 3 SD in any direction of the ﬁrst two principal
components given by the distribution from each respective group (lone AF cohort
or control group B) and British in England and Scotland (GBR) populations an
ethnic outlier. We applied the King robust algorithm with an LD threshold of 0.5,
using R package SnpRelate48, and excluded any duplicated or closely related
samples (second degree or closer).
ARTICLE NATURE COMMUNICATIONS | DOI: 10.1038/s41467-018-06618-y
8 NATURE COMMUNICATIONS |  (2018) 9:4316 | DOI: 10.1038/s41467-018-06618-y | www.nature.com/naturecommunications
Sequencing coverage exomes. As a quality control measure, we ﬁltered regions
that on average had <70% covered with 10 reads or more in either cases or control
groups. Subsequently, samples with mean or median < 35X or < 80% of targeted
region covered with <10 reads, in any of the remaining autosome chromosomes,
were excluded. Second, constitutively cardiac expressed exon regions in the TTN
gene were classiﬁed as low coverage if < 80% were covered with <20 reads on
average.
Sequencing coverage targeted sequencing. We deﬁned the same minimum
criterion for sequencing coverage in this replication study, i.e., constitutively car-
diac expressed exon regions in the TTN gene were classiﬁed as low coverage and
excluded if < 80% were covered with <20 reads on average.
Inference of relatedness in families. Reported family relatedness was inferred
with the King robust algorithm on the ﬁltered genotype dataset with an LD
threshold of 0.5, using R package SnpRelate48. All reported family relationships
were conﬁrmed by the resulting kinship coefﬁcients (Supplementary Fig. 4).
Genetic relationship matrix. The genetic relationship matrix (GRM) was based on
the ﬁltered dataset with an LD threshold of 0.5, excluding monomorphic- and non-
autosomal variants and MAF > 0.01. We used AF family index patients and control
samples to obtain the LD values. The GRM was generated using the methods PC-
AiR and PC-relate available in R package GENESIS49–51.
Genetic analyses. In the genetic analyses of familial AF exomes, we focused on
rare LOF variants. Only family members with the clinical diagnosis of AF were
taken into consideration, since 40–80% of all AF episodes are asymptomatic17,18. In
a pair of monozygotic twins, one randomly chosen individual was excluded from
the association test.
Rare variants were deﬁned as non-common in dbSNP b.142, a MAF below 0.1%
(or absent) in all of the ExAC and 1000 Genomes Project populations, and in an in-
house Danish population of 2000 exomes14,52–54. Only variants with a putative
high deleterious impact were included in the tests, as deﬁned by the Sequence
Ontology project55. Splice site region variants were evaluated with dbscSNV, where
a conservative threshold, AdaBoost and Random Forests scores > 0.9, was set for
splice-altering effects and classiﬁed as LOF variants56.
For the genetic analyses of TTN in early-onset lone AF subjects, only rare LOF
variants residing in constitutively expressed exons were considered, i.e., exons
spliced into at least 90% of the TTN transcripts present in the heart (PSI ≥ 90).
Statistical analyses. We performed a Combined Multivariate and Collapsing
(CMC) GLMM burden test of rare TTNtv residing in constitutively expressed
exons57 on the familial AF cohort and control group A. The GRM was generated
using the methods PC-AiR and PC-relate on the ﬁltered genotype dataset with an
LD-pruning threshold of 0.5 and a minimum MAF of 1%49,50. The tests were
performed using the statistical frameworks GENESIS and SeqVarTools51,58 avail-
able as R packages. A binominal mixed model was ﬁrst ﬁtted under the null
hypothesis using the generated GRM. The ﬁtted mixed model was then used in
conjunction to the burden test to adjust for polygenic random effects. A weight of
one was given to all variants and only variants with internal MAF < 1% were
included. The allele frequencies were calculated using AF family index patients and
control samples. An exome-wide adjusted signiﬁcance threshold P < 2.5 × 10−6 was
considered signiﬁcant.
With quality controlled and ethnically matched samples from the early-onset
lone AF cohort and control group B, we tested the hypothesis of enrichment of rare
TTNtv in AF cases. Only variants with internal MAF < 1% were included. The
burden test was performed with Firth logistic regression and a P < 0.05 considered
signiﬁcant.
Proteomics experiments on human heart tissue biopsies. We used results from
proteomics experiments to evaluate the protein expression level of titin in human
atria compared with human ventricles. Brieﬂy, three cardiac tissue biopsies from
LA, right atria (RA), and LV were obtained from seven patients undergoing mitral
valve surgery, and immediately snap frozen in liquid NO2 and stored (–80 °C).
Protein extraction of biopsies (2 mg per sample) was followed by digestion as
described previously59,60. Desalted digested peptides were fractionated into 12
fractions by micro-ﬂow reverse-phase ultrahigh pressure liquid chromatography.
Following this, samples were separated on 15 cm fused-silica emitter columns (in a
1 h multi-step linear gradient). These were analyzed by online reversed-phase
liquid chromatography coupled to a Q-Exactive Plus quadrupole Orbitrap tandem
MS. Using the MaxQuant software, we processed the raw MS data. To identify
proteins, we used a built-in Andromeda search engine containing human SwissProt
protein entries. A total of 6588 proteins were measured of which 5941 were
quantiﬁed. Titin was identiﬁed in all biopsies and quantitation was based on 2974
distinct peptides that in total cover 68.6% of the titin amino-acid sequence. One LA
sample behaved as an outlier due to very limited input material available in that
particular LA biopsy. The outlier was determined by number of protein identiﬁ-
cations and principal component analysis and it was excluded from further
analyses. Rank analysis was based on summed MS-based protein intensities. Label-
free quantiﬁcation was performed in MaxQuant. Shapiro–Wilk normality test did
not reject the null hypothesis that samples could be drawn from a normal dis-
tribution (P > 0.05 for all chambers), and Bartlett test of homogeneity of variances
rejected the null hypothesis of equal variances between groups (P= 0.04). Protein
intensities measured for titin in atrial and ventricular biopsies were compared using
a two-sided Welch two sample t-test for samples of non-equal variance. Group
means were not found to be statistically signiﬁcantly different for any two cardiac
chambers compared (P= 0.19 for RA versus LA, P= 0.06 for LA versus LV, and
P= 0.84 for RA versus LV), nor for all atrial biopsies compared with all ventricular
samples (P= 0.54). The experiment was not repeated.
Written informed consent was obtained from all study participants. The study
was approved by the scientiﬁc ethics committee for the Capital Region of Denmark
(protocol number 16238).
Zebraﬁsh model. To evaluate the molecular consequences of a titin truncation, we
used a CRISPR/Cas9 generated zebraﬁsh19. The mutant ttn.2sfc9 carries a trunca-
tion at the N-terminal in the proximal I-band. The orthologous human amino-acid
position (p.3048) corresponds to a similar localization as some of the identiﬁed
TTNtv seen in our patients (Table 3, Supplementary Data 2). The mutant zebraﬁsh
was a kind gift from Rahul Deo, USCF, USA, and described in detail in Zou et al.19.
The zebraﬁsh carry a truncating mutation within the zebraﬁsh cardiac TTN
orthologue, ttn.2, so that the resulting protein product is truncated in the I-band.
Histology and Sirius Red staining. Adult zebraﬁsh hearts were dissected from
8 months old adult heterozygous (n= 4) and WT siblings (n= 4). The tissue was
ﬁxed in 24 h at room temperature (RT) in 4% phosphate-buffered saline buffered
formalin (Sigma-Aldrich, Denmark). After ﬁxation, the samples were processed for
parafﬁn embedding through dehydration in graded alcohols, cleared in xylene and
embedded in parafﬁn. In all, 3 µm parafﬁn sections were cut and placed on glass
slides. For Sirius Red staining, the slides were deparafﬁnized and rehydrated in
xylene followed by graded alcohols. The staining was done using a standard
Picosirius stain protocol.
Immunoﬂuorescence. Hearts were isolated from 72 hpf old zebraﬁsh as previously
described61, and stained for α-actinin (Sigma-Aldrich, mouse anti-α-actinin, clone
EA-53, 1:500) and visualized using goat anti-mouse Alexa Fluor 488 secondary
antibody (1:500; Molecular Probes, Invitrogen, DK)61. The hearts were imaged
using a CorrSight (Fei, Germany) spinning disc microscope with an 40X EC Plan
Neoﬂour (0.9NA). Images were post-processed using ImageJ and FigureJ
software62
Image analysis. Following image capture, images were post-processed using Fiji/
ImageJ, by applying a median ﬁlter, and background subtraction. Scale bars were
applied using ImageJ62.
Transmitted electron microscopy. Hearts from 6-month old WT (n= 3), 6-
month old heterozygous siblings (n= 3), 72-h old WT (n= 4) and 72-h old WT
heterozygous siblings (n= 4) were dissected out. Tissues from adults were sepa-
rated into atrium and ventricle (12 samples in total). The samples were ﬁxed in 2%
v/v glutaraldehyde in 0.05 M sodium phosphate buffer (pH 7.4) for 24 h. Following
ﬁxation, samples were brieﬂy rinsed in a sodium cacodylate buffer (0.15 M, pH 7.4).
A 2 h post-ﬁxation step followed (1% w/v OsO4, 0.05 M potassium ferricyanide in
0.12 M sodium cacodylate buffer, pH 7.4). Following the post-ﬁxation incubation,
samples were dehydrated in ethanol and transferred to propylene oxide, before
embedding in Epon. Sections were cut at approximately 80 nm on a Leica UC7
microtome. Sections were collected on copper grids in Formvar supporting
membranes, and stained with uranyl acetate and lead citrate. Samples were imaged
on a Philips CM 100 TEM (Philips, Eindhoven, The Netherlands), operated at an
accelerating voltage of 80 kV. Images were captured with an OSIS Veleta digital
slow scan 2k × 2k CCD camera, and subsequently viewed in the ITEM software
package.
Sarcomere length analysis. The length of the sarcomeres was analyzed using the
TEM images and ImageJ. Using the Feret function in ImageJ, the number of pixels
on the length between the two Z-discs were measured, and the length in µM was
calculated using the scale bar from the microscope. The measured length of each
sarcomere was plotted in Prism6 and analyzed with one-way analysis of variance
and subsequent Tukey’s test.
Electrocardiography recordings on adult zebraﬁsh. All experiments were done
in accordance with the European Convention for the Protection of Vertebrate
Animals used for Experimental and other Scientiﬁc Purposes and the Danish
Animal Experimental board (Personal project license 2017-15-0201-01305).
The zebraﬁsh were anesthetized in 0.03% Tricaine/MS-222 (Sigma-Aldrich, St.
Louis, Missouri, USA) in ﬁsh tank water, and after 5 min the zebraﬁsh were placed
dorsal side down in a damp sponge. The ﬁsh were orally perfused with ﬁsh tank
water containing 0.03% Tricaine using a roller pump (ISM827B, ISMATEC
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Germany) at 2 ml min−1. Two custom made stainless steel electrodes were placed
on top or slightly subcutaneously above the cardiac region using
micromanipulators (Marzhauser MM33, Marzhauser Germany). The electrodes
were connected to a differential AC ampliﬁer (A-M Systems, WA, USA) with the
following ﬁlter settings: Low cut-off ﬁlter= 10 Hz; high cut-off ﬁlter= 1 KHz;
Gain= ×100. Signals were digitized in a PowerLab 4/30 (AD instruments, USA)
and recorded at 10 k s–1 in LabChart 7.0 (AD instruments, USA) using a digital low
pass ﬁlter (cut-off frequency= 50 Hz; active input ampliﬁer= 5 V range; low pass
ﬁlter= 200 Hz; Mains ﬁlter= active). The ECGs were analyzed using minimum 30
consecutive beats, and analyzed beat for beat. The investigators had no knowledge
of genotype status of the Zebraﬁsh during ECG recording and measurement.
Data availability
The datasets generated during analyses have been deposited at the European Genome-
phenome Archive (EGA), which is hosted by EBI and CRG, under accession numbers
EGAS00001003207 and EGAS00001003208. All relevant data are available upon request.
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